S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
NASDAQ:GNLX

Genelux (GNLX) Stock Price, News & Analysis

$4.13
+0.27 (+6.99%)
(As of 04/19/2024 ET)
Today's Range
$3.76
$4.19
50-Day Range
$3.52
$9.01
52-Week Range
$3.42
$40.98
Volume
129,908 shs
Average Volume
117,075 shs
Market Capitalization
$110.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

Genelux MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
723.2% Upside
$34.00 Price Target
Short Interest
Bearish
9.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Genelux in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$171,851 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.81) to ($1.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

776th out of 908 stocks

Pharmaceutical Preparations Industry

339th out of 399 stocks

GNLX stock logo

About Genelux Stock (NASDAQ:GNLX)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

GNLX Stock Price History

GNLX Stock News Headlines

He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
GNLX Stock Earnings: Genelux Misses EPS for Q4 2023
Atossa climbs after cancer therapy update
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
CytomX FY 2023 Earnings Preview
Genelux Stock (NASDAQ:GNLX) Insider Trades
Genelux VP Sold $191K In Company Stock
Genelux GAAP EPS of -$0.20 misses by $0.02
See More Headlines
Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/20/2024
Next Earnings (Estimated)
7/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GNLX
Fax
N/A
Employees
23
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.00
High Stock Price Target
$40.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+723.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,300,000.00
Pretax Margin
-16,645.29%

Debt

Sales & Book Value

Annual Sales
$170,000.00
Book Value
$0.73 per share

Miscellaneous

Free Float
23,722,000
Market Cap
$110.93 million
Optionable
Not Optionable
Beta
-3.21
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Thomas Zindrick J.D. (Age 65)
    Chairman, CEO & President
    Comp: $500k
  • Mr. Sean Ryder J.D. (Age 55)
    General Counsel & Corporate Secretary
    Comp: $380k
  • Ms. Lourie S. Zak (Age 61)
    CFO & Principal Accounting Officer
  • Dr. Joseph Cappello Ph.D. (Age 67)
    Chief Technical Officer
    Comp: $213.08k
  • Dr. Yong Yu Ph.D. (Age 53)
    Senior Vice President of Clinical Development
    Comp: $242.62k
  • Prof. Paul Scigalla M.D. (Age 78)
    Ph.D., Chief Medical Officer
  • Mr. Ralph Smalling B.Sc. (Age 67)
    VP & Head of Regulatory Affairs
  • Ms. Caroline Jewett (Age 59)
    VP & Head of Quality

GNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genelux stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNLX shares.
View GNLX analyst ratings
or view top-rated stocks.

What is Genelux's stock price target for 2024?

4 brokers have issued 1 year target prices for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they anticipate the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 723.2% from the stock's current price.
View analysts price targets for GNLX
or view top-rated stocks among Wall Street analysts.

How have GNLX shares performed in 2024?

Genelux's stock was trading at $14.01 at the beginning of 2024. Since then, GNLX shares have decreased by 70.5% and is now trading at $4.13.
View the best growth stocks for 2024 here
.

When is Genelux's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024.
View our GNLX earnings forecast
.

When did Genelux IPO?

Genelux (GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNLX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners